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Abstract
Purpose: The aim of the study was to report our experience with high-dose-rate interstitial brachytherapy (HDR-
ISBT) in locally advanced and recurrent vulvar cancer. 
Material and methods: Between 2004 and 2014, fourteen women with locally advanced or recurrent vulvar cancer 
were treated using HDR-ISBT in our Centre. High-dose-rate interstitial brachytherapy was performed as a separate 
treatment or in combination with external beam radiotherapy (EBRT) (given prior to brachytherapy). 
Results: Patients were divided into: group I (n = 6) with locally advanced tumors, stages III-IVA after an incisional 
biopsy only, and group II (n = 8) with recurrent vulvar cancer after previous radical surgery. In group I, median follow 
up was 12 months (range 7-18 months); 1-year overall survival (OS) was 83%. Transient arrest of cancer growth or 
tumor regression was noticed in all patients but 4/6 developed relapse. Median time to failure was 6.3 months (range 
3-11 months). The 1-year progression-free survival (PFS) was 33%. In group II, median follow up was 28 months (range 
13-90 months). The 1-year and 3-year OS was 100% and 80%, respectively. The arrest of cancer growth or tumor regres-
sion was achieved in all patients. In 4/8 patients neither clinical nor histological symptoms of relapse were observed 
but 4/8 women experienced relapse. Median time to failure was 31 months (range 13-76 months). The 1-year and 
3-year PFS was 100% and 62.5%, respectively. Two patients (14.3%) in group II had severe late toxicity (G3). 
Conclusions: High-dose-rate interstitial brachytherapy is a well-tolerated treatment option in selected patients 
with advanced or recurrent vulvar cancer. It is a safe and effective treatment modality for advanced and recurrent 
vulvar cancer, yielding good local control with acceptable late treatment related side effects. In our study, patients with 
recurrent vulvar cancer had better results in HDR-ISBT treatment, probably because of the smaller tumor volume. This 
hypothesis should be verified in a larger group of patients. 
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Purpose
Locally advanced and recurrent vulvar cancer may 
present a serious therapeutic problem. It occurs predom-
inantly in elderly patients with severe comorbidities that 
often restrict the surgical treatment options. Interstitial 
brachytherapy is one of the possible treatment modal-
ities in selected patients. Vulvar cancer represents ap-
proximately 4-5% of all gynecological tumors [1,2,3]. It is 
usually classified into two groups: the first is associated 
with human papillomavirus (HPV) infection and usually 
occurs in younger patients; the second is not HPV associ-
ated and is observed mostly in elderly patients with ‘li-
chen sclerosus’ as a predisposing risk factor [2,4]. There 
are several histological types, whereas squamous cell 
carcinoma (SCC) is the most common (95%) [4,5]. It oc-
curs predominantly in postmenopausal women, and the 
age-specific incidence increases with age [5]. The progno-
sis is strongly correlated to lymph node involvement and 
the stage of the disease [4]. Almost 50% of patients have 
advanced disease at presentation [6]. 
The standard treatment for vulvar SCC is surgery. 
External beam radiotherapy (EBRT), brachytherapy, and 
chemotherapy are either adjuvant or standalone treat-
ment options. Over the last 2 decades, the use of prima-
ry radiotherapy for patients with stage III-IVA vulvar 
cancer increased from 18% in 1988 to 30% by 2008 [7], 
but even in combined therapy, 10-20% of women with 
early-stage disease and 50-70% in advanced stages may 
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return [2,4,5,8]. Local recurrences are the most frequent 
pattern of failure, while less common are those located in 
the groin [9]. They usually occur within two years after 
primary therapy. Re-excision is usually the treatment of 
choice for failures localized on the vulva [10]. However, 
this may present a problem, because the blood supply and 
lymphatic drainage after vulvectomy are often disturbed. 
This makes surgical procedures more complex and less 
successful [11]. Vulvar SCC, like other SCC, is sensitive 
to radiation. For many years it was believed that EBRT 
and brachytherapy in the vulvar region, while yielding 
good therapeutic outcome, are associated with significant 
toxicity [6,11]. 
Brachytherapy is an optimal treatment option for pri-
mary and recurrent carcinomas of the vulva, especially in 
patients with serious comorbidities and contraindications 
for surgery. This allows for the delivery of a very high 
radiation dose to the tumor while sparing organs at risk. 
This is especially important for cases where the tumor is 
located close to dose-limiting organs. 
At our Department, high-dose-rate interstitial brachy-
therapy (HDR-ISBT) has been performed for almost thir-
ty years in selected patients with primary advanced or 
recurrent vulvar cancer. The introduction of computed 
tomography (CT) image-guided HDR-BT has allowed for 
3D treatment planning, and has improved the delineation 
of target volumes. The aim of our study was to report our 
experience with HDR-ISBT in locally advanced and re-
current vulvar cancer. 
Material and methods 
Between 2004 and 2014, seventeen women with local-
ly advanced or recurrent vulvar cancer were treated us-
ing HDR-ISBT at our Department. Fourteen patients with 
minimum 7 months follow up were included in a retro-
spective analysis. High-dose-rate interstitial brachyther-
apy was performed as a separate treatment or in combi-
nation with EBRT. External beam radiotherapy was given 
prior to brachytherapy. 
Patients were divided into two groups: group I 
(n = 6) with locally advanced tumors stage III-IVA (1994 
FIGO) after an incisional biopsy only, and group II 
(n = 8) with recurrent vulvar cancer after previous radical 
surgery. Fourteen patients underwent fifteen HDR-ISBT 
procedures (14/15): one woman (group II) had interstitial 
brachytherapy twice because of two recurrences: each in 
different areas on the vulvectomy scar, with a five year 
gap between the treatments. 
Median age in groups I and II was 79.5 years (range: 
64-88) and 57 years (range 45-85), respectively. In both 
groups there were patients with tumors located on the cli-
toris: one in each group. Before undergoing brachythera-
py, women in both groups reported moderate to severe 
local pain, occasional bleeding, and recurring infections 
in the vulvar area. Women with tumors localized near 
the urethra and those after previous EBRT, complained 
of problems with urination. When the tumor was locat-
ed close to the anus, painful defecation was noticed. Pa-
tients in group I complained of vulvar edema, and dry 
or patchy moist desquamation after EBRT (G1 and G2 
according to RTOG/EORTC scale – Radiation Therapy 
Oncology Group/European Organization for Research 
and Treatment of Cancer). 
All patients were disqualified from surgery because 
of the tumor size and location, previous undergone sur-
gery, or comorbidities. Patient and tumor characteris-
tic in Table 1. 5/6 patients in group I were disqualified 
from radical radiochemotherapy because of bad health 
condition, comorbidities, and advanced age. They un-
derwent palliative EBRT (20 Gy in 5 fractions). 1/6 pa-
tient underwent incomplete radical radiochemotherapy 
(50 Gy from 66 Gy planned because of severe toxicity 
and tumor progression). In whole group of patients, the 
disease progressed and women complained of vulvar 
pain and bleeding. They were treated with analgesics 
and antihemorrhagics, but afflictions increased. Three 
patients refused renewed EBRT, two underwent two 
cycles of EBRT 20 Gy in 5 fractions. One woman under-
went incomplete radical EBRT. All patients in group I 
were qualified to palliative brachytherapy and the inter-
stitial option was chosen because tumors were thicker 
than 5 mm. 
In group II, two patients had HDR-ISBT given as 
a “boost” with EBRT (the first: 54 Gy with 4 cycles of cis-
platin, and the second: 50.4 Gy) and six had standalone 
brachytherapy (one had radical EBRT to regional lymph 
nodes). Previous treatment in both groups is shown in 
Table 1. 
Brachytherapy implant procedure 
All patients were hospitalized before the procedure. 
The implantation was performed under general anes-
thesia. The target volume was determined after clinical 
examination, transrectal and/or transvaginal ultrasound, 
CT, or magnetic resonance imaging (MRI) scans. When-
ever possible, flexible catheters were used to prepare the 
temporary implant, otherwise steel needles were used. 
Implants were done with the free hand technique (no 
template used) after Foley catheter insertion. 
Catheters and needles were inserted into the tumor 
in a single plane with a healthy tissue margin of at least 
5 mm. The distance between the catheters/needles was 
9-11 mm (Figures 1 and 2). Antibiotics and analgesics 
were prescribed if necessary. At the end of the treatment, 
the catheters were removed. The Foley catheter was re-
moved the next day. 
Brachytherapy planning and dosimetry 
The treated volume was determined using clinical 
examination and preoperative imaging: transvaginal or 
transrectal ultrasound and, since 2011, CT or MRI scans. 
High-dose-rate brachytherapy was performed with 
afterloading 192Ir source using microSelectron HDR 
(Nucletron, an Elekta Company, Elekta AB, Stockholm, 
Sweden). Before 2011, the treatment plans were calcu-
lated with PLATO BPS v14.2.6 (Nucletron, Veenendal, 
The Netherlands) based on fluoroscopic images. Since 
2011, 3D treatment plans have been computed using the 
Oncentra MasterPlan version, 4.1 Brachytherapy TPS 
(Nucletron, an Elekta Company, Stockholm, Sweden). 
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Table 1. Combined data of all patients (n = 14) with treatment details, pattern of failure, and final outcome 
Group Patient 
number
Primary  
EBRT (total 
dose/number 
of fractions)
Lymph node 
involvement
Yes/No
Comorbidities Tumor  
extent before 
brachytherapy
Brachytherapy 
total dose/
Number of 
fractions
Number  
of cathe-
ters (C)/
Needles (N)
V100 cm
3 Pattern 
of  
failure
Alive 
Yes/No
G
ro
up
 I 
(p
ri
m
ar
y 
ad
va
nc
ed
 d
is
ea
se
 a
ft
er
 in
ci
si
on
al
 b
io
ps
y)
1 20 Gy/5 No AH, MI,  
second 
cancer
Right labia 
majora
42 Gy/12 3 C 13.4 M No
2 2 × 20 Gy/5 No AH, DM, MI Right labia 
majora and 
1/2 left infil-
trating mons 
pubis
35 Gy/10 4 C 40.1 LP No
3 2 × 20 Gy/5 No DM Right and 
left labia 
majora and 
perineum
34.6 Gy/9 5 C 38.1 LP No
4 20 Gy/5  
and 20 Gy/5 
on regional 
lymph nodes
Yes AH, DM, MI Right and 
3/4 left labia 
majora and 
perineum
35 Gy/10 7 C 30 LP No
5 20 Gy/5  
and 20 Gy/5 
on regional 
lymph nodes
Yes AH, MI Left and 
right labia 
majora with 
perineum
31.5 Gy/9 8 C 58.7 RP Yes
6 50 Gy/25 
(planned  
66 Gy) on 
vulva and 
regional 
lymph 
nodes and 
chemotherapy
Yes AH Left labia 
majora 
infiltrating 
clitoris
32 Gy/10 3 C 11.9 M No
G
ro
up
 II
 (a
ft
er
 p
ri
m
ar
y 
ra
di
ca
l v
ul
ve
ct
om
y 
w
it
h 
re
cu
rr
en
t 
di
se
as
e)
7 54 Gy/27 
and chemo-
therapy
Yes In postop-
erative scar 
on left side 
infiltrating 
vagina
24.5 Gy/7 3 C 8.3 LC Yes
8 50.4 Gy/28 Yes AH, MI Left side of 
a postopera-
tive scar
15 Gy/5 3 C 7.6 LC Yes
9 – No AH, MI Near  
postoperative 
scar on left 
side
21 Gy/3 3 N 4 LP No
10 45 Gy to 
regional 
lymph 
nodes 
plus 10 Gy 
“boost” to 
metastatic 
nodes
Yes DM Tumor in left 
postoperative 
scar  
infiltrating 
clitoris
30 Gy/3 5-7 N 39.4 RP No
11 – No Close to 
postoperative 
scar on left
39.6 Gy/12 4 C 6.6 LC Yes
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Cone beam CT imaging (Simulix Evolution, Nucletron, 
Veenendal, The Netherlands) was used for dose distri-
bution calculation. Planning CT scans of the implant 
area were done with slice thickness of 1 mm. The HDR-
ISBT dose was prescribed at 4-6 mm from the applica-
tor surface. In flexible catheter implants, the fraction-
ation dose range was 3-3.7 Gy given twice a day with 
at least six hours interval between the fractions. The 
first fraction was given the same day the catheters were 
inserted. Usually, the first fraction was 5 Gy. For the 
patients in whom needles were used, the dose range 
was 7-10 Gy per fraction, given once a week. If needed, 
both graphic and geometric optimization were done to 
achieve the optimal plan. The volumes receiving 90% 
(V90), 100% (V100), 150% (V150), and 200% (V200) of the 
prescribed dose were calculated. The most important 
organ at risk was the urethra. To evaluate the dose de-
livered to this organ, D2cc and D0.1cc were calculated 
based on the dose volume histogram derived from 3D 
dose distribution (Figure 3). Detailed HDR-ISBT treat-
ment is shown in Table 2. The equivalent dose in 2 Gy 
fractions (EQD2) was calculated by using the following 
formula: 
EQD2 = D (d + (α/β)) / (2 + (α/β)) 
where D is the total dose, d is the dose per fraction, and 
the α/β ratio is considered 10 for the tumor (Table 2). 
The arrest of cancer growth or tumor regression at 
the site of origin was noticed in all patients. Time to pro-
gression, progression-free survival (PFS), overall surviv-
al (OS), and toxicity were analyzed. Time to progression 
was defined as the time in months from the ending of 
brachytherapy until objective tumor progression (local 
or regional recurrence and/or distant metastases). Lo-
cal recurrence was defined as any recurrent disease in 
Group Patient 
number
Primary  
EBRT (total 
dose/number 
of fractions)
Lymph node 
involvement
Yes/No
Comorbidities Tumor  
extent before 
brachytherapy
Brachytherapy 
total dose/
Number of 
fractions
Number  
of cathe-
ters (C)/
Needles (N)
V100 cm
3 Pattern 
of  
failure
Alive 
Yes/No
G
ro
up
 II
 (a
ft
er
 p
ri
m
ar
y 
ra
di
ca
l v
ul
ve
ct
om
y 
 
w
it
h 
re
cu
rr
en
t 
di
se
as
e)
12 – No AH, DM In postoper-
ative scar on 
left infiltrat-
ing perineum
43.4 Gy/13 4 C 11 RP No
13 – No In postoper-
ative scar on 
left infiltrat-
ing perineum
36 Gy/13 3 C 9.3 LP Yes
14* – No Tumor in 
postoperative 
scar on left
Tumor in 
postoperative 
scar on right
32 Gy/10
31.5 Gy/9
3C
3C
10.8
8.4
LC 
twice
No
*Treated twice – both recurrences with HDR-ISBT 
EBRT – external beam radiotherapy, AH – arterial hypertension, DM – diabetes mellitus, MI – myocardial ischemia, C – catheters, N – needles, V100 – volume receiving 
100% of the prescribed dose, LP – local progression, RP – regional progression, LC – local control, M – metastases 
Table 1. Cont.
Fig. 1. High-dose-rate interstitial brachytherapy procedure 
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Fig. 2. High-dose-rate interstitial brachytherapy 3D treatment plan calculated on the basis of computed tomography. Urethra, 
catheter balloon, and rectum were delineated on computed tomography slices to evaluate the exposure to irradiation 
Fig. 3. Dose volume histogram 
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Table 2. Interstitial high-dose-rate brachytherapy 
characteristic 
Group I (n = 6) Group II (n = 9)
Implant
Flexible 6 7
Needles – 2
Number of
catheters 5 (range 3-8) 3 (range 3-4)
needles – 4 (range 3-7)
Implant parameters
V90 40.5 9.9
V100 34 cm
3 (11.9-58.7) 8.5 cm3 (4-39.4)
V150 14.2 4.4
V200 7.3 2.1
ISBT fractionation dose
Catheters 3-3.7 Gy; first 
fraction – 5 Gy
3-3.7 Gy; first 
fraction – 5 Gy
Needles – 7-10 Gy
ISBT total dose
Boost – 19.8 Gy (15-24.5)
With palliative 
EBRT
35 Gy (31.5-42) –
Sole ISBT – 34.4 Gy (21-43.4)
EQD2
Boost – 22 Gy (16.3-27.6)
With palliative 
EBRT
39 Gy (34.6-45.5) –
Sole ISBT – 41 Gy (29.7-50)
ISBT treatment time 5-16 days (median 10 days)
V90 – volume receiving 90% of the prescribed dose, V100 – volume receiving 
100% of the prescribed dose, V150 – volume receiving 150% of the prescribed 
dose, V200 – volume receiving 200% of the prescribed dose, ISBT – interstitial 
brachytherapy, EBRT – external beam radiotherapy, EQD2 – equivalent dose in 
2 Gy fractions 
the primary tumor site. The rest of the recurrences were 
qualified as regional (inguinal or pelvic region) or distant 
metastases. Progression-free survival was defined as the 
time between treatment initiation and tumor progression 
or death from any cause. Overall survival was defined as 
the period from the date of diagnosis to the date of death 
or last follow up. 
Acute and late toxicity was graded according to the 
RTOG/EORTC scale. 
Statistical analysis 
The statistical software “Statistica 10” (StatSoft, Po-
land) was used for statistical analysis. Progression-free 
survival and OS were calculated using the Kaplan-Meier 
method. 
Results 
All patients completed the scheduled treatment with-
out any interruption. In group I, median follow up was 12 
months (range 7-18 months). 1-year OS was 83% (Figure 4). 
Transient arrest of cancer growth at the site of origin 
was noticed in all patients. 5/6 women died within 
18 months from the beginning of therapy. 3/6 developed 
local and 1/6 – regional progression. 2/6 women died 
because of metastatic disease: one due to vulvar cancer 
and the second had a co-existent advanced tonsil carci-
noma with lung metastases. Median time to failure was 
6.3 months (range 3-11 months). One patient is still in fol-
low up (10 months). She developed regional progression 
6 months after brachytherapy (Table 1). The 1-year PFS in 
group I was 33% (Figure 5). 
Fig. 4. Overall survival in both groups (n = 14). Group I  
(n = 6) with locally advanced vulvar cancer. Group II (n = 8) 
with recurrent vulvar cancer
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Fig. 5. Progression-free survival in both groups (n = 14). 
Group I (n = 6) with locally advanced vulvar cancer. 
Group II (n = 8) with recurrent vulvar cancer 
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In group II, median follow up was 28 months (range 
13-90 months). The 1-year and 3-year OS were 100% and 
80%, respectively (Figure 4). The arrest of cancer growth 
or tumor regression was achieved in all patients. In 4/8 
patients (5/9 cases) there were neither clinical nor his-
tological symptoms of relapse during the last control: 
3/4 are alive and followed up, and 1/4 (treated with 
HDR-ISBT twice on each target within 7 and 2 year fol-
low up) died because of myocardial infarcts. The next 4/8 
patients experienced relapse – 3/4 died because cancer 
progression: 1/3 due to local and 2/3 regional recur-
rence. One patient with local recurrence is under surveil-
lance. Median time to failure was 31 months (range 13-76 
months) (Table 1). The 1-year and 3-year PFS was 100% 
and 62.5%, respectively (Figure 5). Significant differences 
in OS according to median V100 (11 cm3) were observed 
(p < 0.02). Tumor volume smaller than median resulted 
in improved OS (Figure 6). There were no complications 
during the implantation. The treatment was well tolerat-
ed by all patients. In both groups acute toxicity predom-
inantly included vulvar edema and radiation mucositis, 
which dissolved within 6-8 weeks after the treatment. 
These symptoms occurred mainly within 4 days and 
healed usually within 12 weeks. All women reported 
mild to moderate vulvar area pain. Two patients (14.3%) 
in group II had severe late toxicity (G3), namely soft tis-
sue necrosis. One of them died because of regional cancer 
progression. The second is under surveillance without 
active disease. Skin necrosis occurred in the previously 
treated area. The first patient had tumor previously lo-
cated on the clitoris. She reported to our department with 
recurrent vulvar cancer situated very close to the urethra. 
High-dose-rate interstitial brachytherapy on the vulvar 
tumor was performed (total dose 30 Gy in 3 fractions 
given once a week with steel needles) and EBRT to re-
gional lymph nodes (45 Gy with a 10 Gy boost to a met-
astatic lymph node identified by fine needle aspiration). 
The second patient underwent HDR-ISBT as a boost with 
concomitant chemoradiotheray (EBRT: 54 Gy to the vulva 
and regional lymph nodes in 2 Gy fractions along with 
4 cycles of cisplatin out of 6 planned; due to deteriorating 
blood parameters the remaining two cycles could not be 
administered). 
Discussion 
Vulvar cancer is usually diagnosed in advanced stag-
es, as well as in elderly patients with severe comorbidi-
ties, making the treatment decisions difficult. Advanced 
age has been identified as a prognostic factor for survival 
in vulvar cancer [12]. In our study, the median age was 
78 years. Our group was relatively small and not homo-
geneous but vulvar cancer is rare condition. Palliative 
ISBT was chosen only for individually qualified patients 
with advanced disease (group I) and selected patients 
with vulvar cancer local recurrence with salvage or cu-
rative intent. Patients in group I underwent previous 
EBRT but the disease progressed. They complained of 
persistent vulvar pain and bleeding. Some patients re-
fused renewed EBRT, and others received earlier two 
courses of palliative or incomplete radical radiotherapy 
on the vulvar area. In spite of analgesic and antihemor-
rhagic treatment, patients complaints increased. Then 
the decision of palliative ISBT was made. The intersti-
tial option was chosen because tumors were thicker than 
5 mm, and only interstitial treatment gave the possibili-
ty to fully cover the target volume. The short follow up 
in that group is a limitation of the study, however 5/6 
patients died within 18 months after HDR-ISBT. One is 
under control with 10 months follow up. The number 
of publications covering interstitial brachytherapy for 
advanced or recurrent vulvar carcinoma is still limit-
ed [11,13,14], and there are no established recommen-
dations for vulvar cancer brachytherapy. According to 
American Brachytherapy Society guidelines for vaginal 
lesions, ISBT can be performed in tumors, which are ap-
proximately 0.5 cm thick [15,16]. 
The standard treatment in vulvar cancer is surgery 
with optional adjuvant treatment when indicated [10]. 
However, even after combined therapy, vulvar cancer 
may recur [17]. The reported rate of tumor recurrence 
ranges from 15-37% [18,19], and some of them may be oth-
er independent primary lesions [20,21]. In vulvar squa-
mous cell carcinoma, approximately 40-60% of failures 
develop within two years after the primary treatment and 
most of them are local [19]. It is estimated that about 10% 
of patients experience recurrence 5 or more years after 
diagnosis [22]. Loco-regional failure is an important risk 
factor for distant metastatic disease. Vulvar cancer recur-
rences often cannot be re-excised because of the prox-
imity of the rectum, bladder, or urethra [15,20,23]. For 
patients with advanced or recurrent cancer who are not 
eligible for surgery, radiotherapy or radiochemotherapy 
is a beneficial treatment option [12,13,14,17]. In our group 
of patients, women with primary advanced tumors were 
qualified to palliative treatment except one with incom-
plete radiochemotherapy due to tumor progression. All 
patients in both groups were disqualified from surgical 
procedures because of tumor location, previous definite 
surgery, or comorbidities. 
Fig. 6. Overall survival according to median V100. Median 
V100 = 11.0 cm3 
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Modern EBRT and brachytherapy with advanced 
equipment and precise treatment planning offers a highly 
conformal technique with low associated toxicity. Inter-
stitial brachytherapy is in particular an effective, non-ag-
gressive, and individualized therapy given in a short pe-
riod of time. Even in large, advanced or recurrent tumors, 
ISBT allows the reduction of the dose to organs at risk 
with very high doses given directly to the tumor. This 
is particularly important in elderly patients with severe 
comorbidities and contraindications for surgical proce-
dures. Interstitial brachytherapy provides good comfort, 
even in palliative treatment. It reduces treatment time 
and irradiated volume, thus offering relief in ulcerated 
and painful tumors [14,24]. This is especially important 
in patients who have undergone previous EBRT in the 
treated area [25]. 
In our group, all implants were inserted with the free-
hand technique. When most of the tumor was located on 
the vulva, particularly in the labia, plastic catheters were 
chosen to prepare a temporary implant. Flexible catheters 
offer better dose distribution and higher quality of treat-
ment for patients. Interstitial brachytherapy given in a short 
time with a relatively small area of irradiation resulted in 
very good treatment tolerance, and all women completed 
the scheduled therapy without any interruption. 
Interstitial brachytherapy in primary advanced dis-
ease allowed the achievement of palliative effects: re-
duced afflictions and transiently arrested growth of the 
tumor. In the group treated with salvage or curative in-
tent, 50% of the patients had no clinical or histological 
symptoms of cancer after HDR-ISBT at the last control. 
In our study, significant differences in OS according 
to median V100 were observed. Smaller tumor volume re-
sulted in improved OS. It is well described in literature 
that tumor volume has a great impact on treatment re-
sults and survival: larger tumors have worse prognosis 
[19,25,26]. Patients with primary advanced disease were 
older with severe comorbidities. They could not be treat-
ed with radical intention because of the delay before the 
first visit. Patients with recurrent disease were younger 
and they were in regular controls after previous treat-
ment. This led to the diagnosis of recurrent disease at an 
early stage. 
It is well known that failures usually occur during the 
first two years after previous treatment but in some cas-
es they may appear as late as within five or more years. 
Sometimes three or more local recurrences are observed, 
and some of them may be other independent primary 
tumors, occurring especially in patients with diagnosed 
‘lichen sclerosus’ [9]. Nicoletto et al. had 46% of the sec-
ond local recurrences in his study [27], and Wooderlink 
et al. observed a second or further local failure in 72% of 
cases [9]. 
There is no standard treatment schedule in HDR-ISBT 
in vulvar cancer, and it is difficult to compare doses be-
tween the published studies because of the insufficient 
homogeneity of the groups. In our study, the total dos-
es in both groups were similar (except patients with BT 
boost). In the available literature, HDR-ISBT doses range 
between 30-42 Gy as a standalone treatment [13] and 
16-20 Gy in combination with EBRT [25]. Beriwal et al. 
investigated a group of patients with primary and recur-
rent vulvovaginal malignancy. Thirteen patients received 
ISBT and the median dose of HDR-ISBT was 18.75 Gy in 
five fractions (EQD2 21.5 Gy) in combination with EBRT. 
No acute early toxicity was observed. Two patients (11%) 
developed grade 3/4 late toxicity (rectovaginal fistula 
and chronic vaginal ulceration) [28]. In our group grade 
1 and 2 acute toxicity included vulvar edema and radi-
ation mucositis and pain that was resolved within 6-8 
weeks after the treatment. No grade 3 or 4 acute toxici-
ty was observed. Severe late toxicity G3 occurred in two 
patients with recurrent vulvar cancer. It was persistent 
skin and soft tissue necrosis (ulceration). One of them 
died because of regional cancer progression. The second 
is in regular control without active disease. Skin necrosis 
developed within the previously treated area. 
In our group, two patients had tumors located on the 
clitoris. Both of them died: one because of regional tumor 
progression and the other because of distant metastases. 
It is known that patients with vulvar SCC with clitoral 
involvement have a worse prognosis. Some authors ob-
served more positive groin lymph nodes in patients with 
clitoral involvement, probably because of the size, inva-
sion depth of the clitoral tumor, and more direct lym-
phatic drainage from the clitoris to groin nodes [18]. 
Conclusions 
Interstitial HDR brachytherapy is a well-tolerated 
treatment option in selected patients with advanced or 
recurrent vulvar cancer. Interstitial HDR brachytherapy 
is a safe and effective treatment modality for advanced 
and recurrent vulvar cancer, yielding good local control 
with acceptable late treatment-related side effects. In our 
study, patients with recurrent vulvar cancer had better 
results in HDR-ISBT treatment, probably because of the 
smaller tumor volume. This hypothesis should be veri-
fied in a larger group. 
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